Drug Trial Radar · NCT02679755
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jul 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
252
Actual
Start
Mar 9, 2016
Primary completion
Jul 25, 2019
Study completion Jul 25, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive, her2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate.
Conditions
- Breast Cancer
Interventions
PalbociclibDrug
125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
LetrozoleDrug
2.5 mg/d tablets orally on a continuous regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (All Causalities)Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
- Number of Participants With Treatment-Emergent Adverse Events by Severity (All Causalities)Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
- Number of Participants With Treatment-Emergent Adverse Events (Palbociclib-Related)Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
- Number of Participants With Treatment-Emergent Adverse Events by Severity (Palbociclib-Related)Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
- Number of Participants With Serious Adverse Events (All Causalities and Palbociclib-Related)Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
Benjamin Carl Forster
North Sydney, New South Wales, Australia
Dr. Alexander Maxwell Menzies
North Sydney, New South Wales, Australia
HPS Pharmacies - North Sydney
North Sydney, New South Wales, Australia
Mater Hospital Sydney
North Sydney, New South Wales, Australia
Professor Frances Mary Boyle
North Sydney, New South Wales, Australia
Royal North Shore Hospital - Clinical Trials Pharmacy
St Leonards, New South Wales, Australia
Royal North Shore Hospital, Dept. of Medical Oncology
St Leonards, New South Wales, Australia
Icon Cancer Care Wesley
Auchenflower, Queensland, Australia
River City Pharmacy
Auchenflower, Queensland, Australia
Icon Cancer Care Chermside
Chermside, Queensland, Australia
Icon Cancer Care South Brisbane
South Brisbane, Queensland, Australia
Icon Cancer Care, Corporate Office
South Brisbane, Queensland, Australia
Icon Cancer Care Southport
Southport, Queensland, Australia
Flinders Medical Centre-Pharmacy Department
Bedford Park, South Australia, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Monash Health
Clayton, Victoria, Australia
Peter MacCallum Cancer Centre Pharmacy
Melbourne, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Sunshine Hospital Pharmacy
St Albans, Victoria, Australia
Sunshine Hospital
St Albans, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Pharmacy Department
Murdoch, Western Australia, Australia
The Gujarat Cancer & Research Institute, M.P Shah Cancer Hospital
Ahmedabad, Gujarat, India
Manipal Hospital
Bangalore, Karnataka, India
HealthCare Global Enterprises Ltd.
Bangalore, Karnataka, India
Kasturba Hospital
Manipal, Karnataka, India
Tata Memorial Centre, Tata Memorial Hospital
Mumbai, Maharashtra, India
Meditrina Institute Of Medical Sciences
Nagpur, Maharashtra, India
Shatabdi Hospital
Nashik, Maharashtra, India
Deenanath Mangeshkar Hospital and Research Center
Pune, Maharashtra, India
Sahyadri Super Speciality Hospital
Pune, Maharashtra, India
Rajiv Gandhi Cancer Institute And Research Centre
New Delhi, National Capital Territory of Delhi, India
Dr. B.R.A Institute Rotary Cancer Hospital, All India Institue of Medical Sciences
New Delhi, National Capital Territory of Delhi, India
Apollo Speciality Hospital
Chennai, Tamil Nadu, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.